Koios Medical and iCAD Join Forces to Revolutionize Breast Cancer Detection at ECR 2025

In a significant development in the realm of breast cancer detection, Koios Medical and iCAD have announced a strategic reseller partnership to deliver an integrated, AI-powered, multi-modality solution at the European Congress of Radiology (ECR) 2025. This collaboration combines iCAD's ProFound AI Breast Health Suite for mammography with Koios SmartUltrasound, creating a comprehensive, end-to-end AI suite for breast cancer screening and detection.

The partnership aims to streamline AI implementation across both mammography and breast ultrasound, providing radiologists with an enhanced workflow from screening to diagnosis. Koios SmartUltrasound, an AI-based software platform, has been proven to accurately detect and diagnose both thyroid and breast cancers in ultrasound exams. By integrating this technology with iCAD's ProFound AI Breast Health Suite, radiologists can benefit from advanced AI algorithms in both systems, leading to more accurate and reliable diagnoses.

The increasing utilization of ultrasound in cancer detection, particularly for women with dense breast tissue, makes this integration particularly relevant in today's evolving healthcare landscape. Over 40% of women in the US have dense breast tissue, which can make mammography less effective in detecting breast cancer. Ultrasound is a widely available and effective alternative to mammography, using no ionizing radiation and is a standard of care for cancer diagnosis.

Chad McClennan, President & CEO of Koios Medical, Inc., expressed his enthusiasm about the collaboration: "iCAD has long been a leader, the pioneer in AI for breast imaging. It is an honor to collaborate with a company with an unmatched track record of improving clinical outcomes for patients and a rich history of innovation." Dana Brown, President and CEO of iCAD, added, "This partnership reinforces iCAD’s commitment to delivering innovative AI solutions that empower radiologists and improve patient outcomes."

By offering an integrated 'breast AI suite' that includes both iCAD's ProFound AI and Koios SmartUltrasound, the partnership enables a more comprehensive, AI-enhanced patient pathway. Streamlining AI acquisition and implementation across both mammography and breast ultrasound is a logical and necessary step forward in breast imaging, as breast imaging radiologists have long embraced innovation and are rapidly adopting best-of-breed AI solutions.

Koios and iCAD will be attending ECR 2025 (Booth: AI-27 – Hall X1) from Wednesday, February 26 to March 2, 2025, in Vienna, Austria. To request a meeting or book a demo, please visit .

In conclusion, the strategic reseller partnership between Koios Medical and iCAD is set to revolutionize breast cancer detection by offering a comprehensive, AI-powered, multi-modality solution at ECR 2025. This collaboration addresses the growing need for effective, radiation-free imaging methods and leverages AI-driven technologies to improve diagnostic accuracy and workflow efficiency, ultimately enhancing patient outcomes.